Oncology

Experimental treatment effective in melanoma patients resistant to drugs that target BRAF.

Adding a building block found in DNA could aid healthy cell production in cancer patients, study finds.

Study finds drawing blood can be a powerful therapeutic in extracorporeal photopherisis.

Vaccine therapy stimulates immune defenses.

Ashley Feldt, PharmD, MBA, director of pharmacy, oncology at Aurora Health Care discusses how technology and remote medication preparation help improve oncology pharmacy.

Patients who received brentuximab vedotin post-transplant lived longer without disease progression than those on supportive care.

Nivolumab treats patients with unresectable or metastatic melanoma who no longer respond to other drugs.

Olaparib (Lynparza) was approved with companion diagnostic that detects mutations in BRCA genes.

Olaparib treats women with advanced ovarian cancer associated with defective BRCA genes.

Treatment shows promising anti-tumor activity.

Bayer HealthCare and Cardinal Health today announced the signing of a 15-year agreement for the contract manufacturing of Xofigo (radium Ra 223 dichloride). As part of the agreement, Cardinal Health will build a state-of-the art, 64,000 square foot facility in Indianapolis, which will be dedicated exclusively to the manufacturing of Xofigo. Product manufactured at this facility will primarily be distributed in the United States and Canada.

Recently approved drugs for the treatment of cancer include Cyramza, Sylvant, Zykadia, Beleodaq, Zydelig, and Keytruda.

Perjeta (pertuzumab) is now approved for the neoadjuvant treatment of breast cancer.

Understanding the needs of seniors with cancer and helping them to manage the complexities of the treatment process are essential to successful patient engagement and improved clinical outcomes.

FL118 could be effective in treating late stage cancers.

Researchers pinpoint method to reverse cancer cell resistance to chemotherapy.

Researchers find that negatives from daily aspirin outweigh the positives.

Ramucirumab receives third indication of 2014.

The FDA today approved a new indication for ramucirumab for the treatment of metastatic non-small cell lung cancer.

Targeted radiation may also be useful in treating other diseases.

Cimetidine has clinically important benefits in improving colon cancer survival and preclinical evidence shows that this benefit may extend to other types of cancer.

New indication approved for drug to treat patients with HCM, a complication that results from cancer-driven increases in bone resorption.

Agent found to stop growth and spread of prostate cancer with a common chromosomal abnormality.

ASHP today recognized the work of the late Jerod M. Loeb, Ph.D., a tireless patient safety advocate, with the ASHP Board of Directors Award of Honor. Loeb's widow, Sherri, accepted the award during the opening session of ASHP's Midyear Clinical Meeting in Anaheim, CA. Dr. Loeb passed away in 2013 from metastatic prostate cancer.

Primary ADT associated with decreased survival in localized prostate cancer patients.

According to a new study, a CCR5-blocking drug used to treat HIV may also be able to slow prostate cancer metastasis.

Preliminary evidence indicates that new treatment is both safe and effective.

Pfizer's phase 3 study of its anaplastic lymphoma kinase inhibitor, crizotinib, provides good news for patients with ALK-positive advanced non-small cell lung cancer.

The OTC antacid is being investigated for its potenial to combat colon cancer.

Alcohol use is responsible for an estimated 3.5% of cancers in the United States, but affects the risk of developing some cancers more than others.